The DOI matches its Crossref record.
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients
Abstract
An important step in the oncogenic transformation of hemopoietic cells and the subsequent development of leukemia is the proliferation of tumor cells in the absence of exogenous growth factors. In most cases of chronic myelocytic leukemia and in some cases of acute myelocytic leukemia and acute lymphocytic leukemia, the bcr-abl oncogene is involved in this process. Although the BCR-Abl oncoprotein demonstrates enhanced tyrosine kinase activity in leukemic cells, the mechanism by which this leads to growth factor independence remains poorly defined. One proposed mechanism is the activation of cytokine signal transduction pathways, possibly by an autocrine loop involving IL-3 and/or granulocyte-macrophage CSF. Examination of several different cell lines expressing BCR-Abl demonstrates that some of these cells have constitutive activation of the JAK/STAT signaling pathway. We have found the constitutive activation of STAT5 in most, but not all, cell lines expressing BCR-Abl. This constitutive activation of STAT5 is variably associated with a corresponding activation of JAK kinases. Ab blocking studies show that the activation of STAT5 in these cell lines cannot be attributed to the activation of an IL-3/granulocyte-macrophage CSF-driven autocrine loop. Interestingly, samples of peripheral blood cells derived from patients with acute myelocytic leukemia and chronic myelocytic leukemia, which express BCR-Abl, demonstrate constitutive activation of STAT family members. These studies suggest that in a variety of leukemic states, BCR-Abl may use a bypass mechanism to activate cytokine signal transduction pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Suppressors of cytokine signalling (SOCS) in the immune system
Alexander, W. S. (2002) · Nature Reviews Immunology · doi:10.1038/nri818 · Cited by 645
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633
Imada, K., & Leonard, W. J. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00018-3 · Cited by 610
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
Piazza, R., Valletta, S., Winkelmann, N., Redaelli, S., Spinelli, R., Pirola, A., Antolini, L., Mologni, L., Donadoni, C., Papaemmanuil, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2495 · Cited by 403
Horita, M., Andreu, E. J., Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F., & Fernandez-Luna, J. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.977 · Cited by 366
Signal transducer and activator of transcription proteins in leukemias
Benekli, M., Baer, M. R., Baumann, H., & Wetzler, M. (2003) · Blood · doi:10.1182/blood-2002-04-1204 · Cited by 325
The Jak-Stat pathway in normal and perturbed hematopoiesis
Ward, A. C., Touw, I., & Yoshimura, A. (2000) · Blood · doi:10.1182/blood.v95.1.19 · Cited by 313
The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2
Kamizono, S., Hanada, T., Yasukawa, H., Minoguchi, S., Kato, R., Minoguchi, M., Hattori, K., Hatakeyama, S., Yada, M., Morita, S., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010074200 · Cited by 311
Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2
Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J. C., Williams, I. R., Lee, C.-K., Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00067-8 · Cited by 303
Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203947 · Cited by 290
(2003) · PubMed · Cited by 272
Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., & Skorski, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1229 · Cited by 271
Turkson, J., Bowman, T., Adnane, J., Zhang, Y., Djeu, J. Y., Sekharam, M., Frank, D. A., Holzman, L. B., Wu, J., Sebti, S., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7519 · Cited by 258
Redell, M. S., Ruiz, M. J., Alonzo, T. A., Gerbing, R. B., & Tweardy, D. J. (2011) · Blood · doi:10.1182/blood-2010-04-280123 · Cited by 257
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256
STAT signaling in the pathogenesis and treatment of leukemias
Lin, T. S., Mahajan, S., & Frank, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203486 · Cited by 205
Campbell, C. L., Jiang, Z., Savarese, D. M. F., & Savarese, T. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63940-5 · Cited by 151
Schuringa, J. J., Chung, K. Y., Morrone, G., & Moore, M. A. S. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041024 · Cited by 140
“A constitutive activation of STAT5 has been observed in acute myeloid leukemia (21– 24), CML (25, 26), and idiopathic myelofibrosis (49), either as a result of chromosomal translocations such as Bcr/Abl in the case of CML, or possibly due to a disturbed cytokine production by leukemic blasts themselves or the surround…”
BackgroundInfluential
Metadata
- Authors
- Chai, S. K., Nichols, G. L., & Rothman, P.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-11
- Volume
- 159
- Issue
- 10
- Pages
- 4720-4728
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2106515248
- Cited by
- 280
- References
- 0
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.